

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

HCC827 PFR1

RRID:CVCL_DH92

Type: Cell Line

Proper Citation

RRID:CVCL_DH92

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_DH92

Proper Citation: RRID:CVCL_DH92

Description: Cell line HCC827 PFR1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:20129249](#)

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC827 PFR1

Synonyms: HCC827 PFR-1

Cross References: cancercellines:CVCL_DH92, GEO:GSM466326, Progenetix:CVCL_DH92, Wikidata:Q54881795

ID: CVCL_DH92

Hierarchy: cvcl_2063

Record Creation Time: 20220427T220319+0000

Record Last Update: 20260829T233635+0000

Ratings and Alerts

No rating or validation information has been found for HCC827 PFR1.

No alerts have been found for HCC827 PFR1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sealover NE, et al. (2024) In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies. iScience, 27(1), 108711.

Zhang Q, et al. (2023) VE-822 upregulates the deubiquitinase OTUD1 to stabilize FHL1 to inhibit the progression of lung adenocarcinoma. Cellular oncology (Dordrecht), 46(4), 1001.

Nishi W, et al. (2023) Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system detecting human PD-1 microclusters. Nature communications, 14(1), 3157.

Theard PL, et al. (2020) Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer. eLife, 9.

Topper MJ, et al. (2017) Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell, 171(6), 1284.